Table 2. Incidence Rates of Composite Cardiovascular Events in the Finerenone in Chronic Kidney Disease and Type 2 Diabetes: Combined FIDELIO-DKD and FIGARO-DKD Trial Programme Analysis (FIDELITY) Trial.

eGFR	Composite cardiovascular events (incidence rate per 100 patient-years [95% CI])a
	UACR <300 mg/gb			UACR ≥300 mg/g
	Placebo (n = 2133)	Finerenone (n = 2196)	HR for finerenone vs placebo (95% CI)	Placebo (n = 4370)	Finerenone (n = 4321)	HR for finerenone vs placebo (95% CI)
≥90	2.38 (1.03-4.29)c	1.94 (0.78-3.62)c	0.57 (0.19-1.68)c	3.78 (2.91-4.75)d	2.56 (1.86-3.37)d	0.66 (0.45-0.97)d
60-<90	3.57 (2.77-4.48)c	2.98 (2.29-3.76)c	0.82 (0.57-1.16)c	4.76 (4.11-5.45)d	4.49 (3.86-5.17)d	1.01 (0.82-1.23)d
45-<60	4.53 (3.72-5.42)d	3.26 (2.57-4.03)d	0.72 (0.54-0.98)d	5.70 (4.79-6.70)e	4.69 (3.89-5.56)e	0.83 (0.65-1.07)e
30-<45	4.93 (4.00-5.95)e	4.89 (3.98-5.89)e	0.98 (0.73-1.30)e	6.03 (5.14-6.99)e	5.84 (4.97-6.79)e	0.96 (0.77-1.19)e
<30	6.54 (4.19-9.40)e	5.85 (3.75-8.41)e	0.82 (0.44-1.52)e	8.74 (6.78-10.93)e	6.89 (5.13-8.90)e	0.75 (0.51-1.09)e

Abbreviations: eGFR, estimated glomerular filtration rate; HR, hazard ratio; UACR, urine albumin to creatinine ratio; KDIGO, Kidney Disease: Improving Global Outcomes.

^a P value for interaction = 0.66.

^b A total of 230 patients with UACR less than 30 mg/g were included in FIDELITY because of variability between screening and baseline results.

^c Moderate KDIGO risk category.

^d High KDIGO risk category.

^e Very high KDIGO risk category.